ALAndrea Laslop

Andrea Laslop

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Laslop has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of treatments for sarcopenia: new challenges, opportunities and perspectives

    by Leo Westbury, Elizabeth M. Curtis, Ewa Balkowiec-Iskra, Antonio Cherubini, Mario Miguel Coelho da Silva Rosa, Paolo Foggi, Yury Kiselev, Andrea Laslop, Sif Ormarsdóttir, Maria Concepcion Prieto Yerro, et al.

    Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited. Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing. Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.

  • Top Cited Papers

    Novel approaches to the stratified management of knee osteoarthritis

    by Nicholas R. Fuggle, Roland Chapurlat, Andrea Laslop, Nasser Al-Daghri, Majed Alokail, Jotheeswaran Amuthavalli Thiyagarajan, Ewa Balkowiec-Iskra, Francis Berenbaum, Angie Botto-Van Bemden, John-Joseph Borg, et al.

    Knee osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbidity. If step changes are to be made in the management of knee osteoarthritis, novel patient stratification approaches are needed to identify the most effective treatment for individual patients. Numerous methods for stratifying patients with knee osteoarthritis can be employed; clinical presentation, including co-morbidity and pain phenotype, can influence treatment decisions, and there is a rich history of imaging biomarker use, both from conventional radiographs and, since its development, via MRI, in identifying patients at risk of disease progression, and the latter facilitates the detection of synovitis. The development of novel biochemical biomarkers and the rapid growth of ‘-omics’ technologies provide fresh opportunities to deploy these advances in the stratification of patients with knee osteoarthritis. The health economic landscape in this area is developing, and scoping work has highlighted the need for further studies.


  • Top Cited Papers
    Open Access

    Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

    by Harjit Pal Bhattoa, Samuel Vasikaran, Ioulia Trifonidi, Georgia Kapoula, Giovanni Lombardi, Niklas Rye Jørgensen, Richard Pikner, Masakazu Miura, Roland Chapurlat, Mickael Hiligsmann, et al.

    Purpose The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. Methods Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. Results Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. Conclusion We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.


  • Open Access

    Impact of dementia and mild cognitive impairment on bone health in older people

    by Elizabeth M. Curtis, Mario Miguel, Claire McEvoy, Andrea Ticinesi, Carla Torre, Nasser Al-Daghri, Majed Alokail, Ewa Bałkowiec-Iskra, Olivier Bruyère, Nansa Burlet, et al.

    Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored. Discussion will focus on how changes in brain and bone signalling can underly associations between these conditions, and will consider the molecular and cellular drivers in the context of inflammation and the gut microbiome. There is a complex interplay between nutritional changes, which may precede or follow the onset of mild cognitive impairment (MCI) or dementia, and bone health. Polypharmacy is common in patients with MCI or dementia, and there are difficult prescribing decisions to be made due to the elevated risk of falls associated with many drugs used for associated problems, which can consequently increase fracture risk. Some medications prescribed for cognitive impairment may directly impact bone health. In addition, patients may have difficulty remembering medication without assistance, meaning that osteoporosis drugs may be prescribed but not taken. Cognitive impairment may be improved or delayed by physical activity and exercise, and there is evidence for the additional benefits of physical activity on falls and fractures. Research gaps and priorities with the aim of reducing the burden of osteoporosis and fractures in people with MCI or dementia will also be discussed.


  • Top Cited Papers
    Open Access

    Evidence-Based Guideline for the management of osteoporosis in men

    by Nicholas R. Fuggle, Charlotte Beaudart, Olivier Bruyère, Bo Abrahamsen, Nasser Al-Daghri, Nansa Burlet, Manju Chandran, Mario M. Rosa, Bernard Cortet, Céline Demonceau, et al.

    Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.


  • Open Access

    Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

    by Vito Annese, Cristina Avendaño-Solá, Ferdinand Breedveld, Niklas Ekman, Thijs J Giezen, Fernando Gomollón, Pekka Kurki, Tore Kristian Kvien, Andrea Laslop, Lluís Puig, et al.

    Authors byline as per print journal:Vito Annese, MD, PhD; Cristina Avendaño-Solá, MD, PhD; Professor Ferdinand Breedveld, MD; Niklas Ekman, PhD; Thijs J Giezen,


  • Volume 12 Contents index

    by K. Kühn, Darryl D. D’lima, S Hashimoto, M. Lotz, Ian W. Holloway, M. V. Kayser, David E. Lee, David S Bader, Gerald Bentley, Mark A. Knight, et al.